Globus Medical (NYSE:GMED) Stock Gets Downgrade from BMO Capital Markets

Globus Medical (NYSE:GMED) was downgraded by research analysts at BMO Capital Markets from an “outperform” rating to a “market perform” rating in a research report issued on Friday, Marketbeat Ratings reports. They presently have a $78.00 target price on the medical device company’s stock, down from their previous target price of $94.00. BMO Capital Markets‘s target price points to a potential upside of 10.38% from the stock’s previous close.

Other research analysts have also recently issued research reports about the stock. Royal Bank Of Canada decreased their price objective on shares of Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a report on Thursday, October 1st. Zacks Research upgraded shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, August 10th. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a research report on Friday, October 9th. Wells Fargo & Company reduced their price target on shares of Globus Medical from $103.00 to $99.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Finally, Truist Financial decreased their price target on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a report on Thursday, July 16th. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $96.92.

Globus Medical Trading Down 13.2%

Shares of GMED opened at $70.67 on Friday. The stock has a market cap of $9.49 billion, a P/E ratio of 17.36, a price-to-earnings-growth ratio of 1.14 and a beta of 0.98. Globus Medical has a 1 year low of $70.39 and a 1 year high of $101.40. The stock’s 50-day moving average price is $77.20 and its two-hundred day moving average price is $83.18.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Thursday, November 5th. The medical device company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.20 by $0.03. The company had revenue of $763.72 million during the quarter, compared to analysts’ expectations of $792.39 million. Globus Medical had a return on equity of 14.51% and a net margin of 17.76%. Globus Medical’s revenue was down .7% on a year-over-year basis. During the same period in the prior year, the business posted $1.18 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, equities analysts forecast that Globus Medical will post 4.99 EPS for the current year.

Insider Activity

In other news, Director James R. Tobin sold 30,000 shares of Globus Medical stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the transaction, the director owned 15,000 shares in the company, valued at $1,118,700. The trade was a 66.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Stephen Zarrilli sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total value of $2,176,000.00. Following the completion of the transaction, the director owned 25,000 shares of the company’s stock, valued at $2,176,000. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 60,000 shares of company stock worth $4,838,400 in the last 90 days. Corporate insiders own 18.38% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Washington Trust Advisors Inc. grew its position in Globus Medical by 116.8% in the second quarter. Washington Trust Advisors Inc. now owns 45,006 shares of the medical device company’s stock valued at $3,556,000 after purchasing an additional 24,250 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Globus Medical during the second quarter worth about $1,858,000. WCM Investment Management LLC bought a new stake in Globus Medical during the first quarter worth about $16,965,000. Public Employees Retirement System of Ohio acquired a new position in Globus Medical during the second quarter valued at approximately $7,941,000. Finally, Congress Asset Management Co. boosted its position in Globus Medical by 6.6% during the third quarter. Congress Asset Management Co. now owns 361,026 shares of the medical device company’s stock valued at $27,041,000 after purchasing an additional 22,401 shares during the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

Key Headlines Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, offering potential support for shareholder returns. Third-quarter results and repurchase announcement
• Neutral Sentiment: Analyst views were mixed: Canaccord and Needham cut their price targets but maintained Buy ratings, while Wells Fargo slightly raised its target and kept an Overweight rating. The company is also seeking acquisitions, though the provided report does not detail potential deals. Report on acquisition plans
• Negative Sentiment: Revenue of $763.7 million missed the $792.4 million analyst estimate and declined 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion is below the roughly $3.2 billion consensus; management cited spine-product launch delays and weak Nevro sales, weighing on expectations despite EPS guidance being broadly in line. Q3 call highlights and outlook
• Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target, adding to concerns about the outlook. Coverage of the stock decline

Globus Medical Company Profile